61. Cancer Center is currently the first to participate in an international clinical trial using aprocess called Photopheresis to treat patients with graft vs. host disease. http://www.urmc.rochester.edu/cancercenter/press062199.htm

About Us Home News Other Links Cancer Center Press Releases June 21, 1999 University of Rochester Cancer Center First to Participate in International Clinical Trial The trial compares the use of Extracorporeal Photopheresis (ECP) in conjunction with standard therapy versus standard therapy alone for the treatment of Chronic Graft vs. Host Disease. Jane Liesveld, M.D., Director of the Bone Marrow Transplant Unit is currently directing the trial which is sponsored by Therakos. During the trial the patient is treated with an instrument that exposes specific blood cells to ultraviolet light with the combination of medication. This is a process of removing and separating specific cells of the blood and returning all but the cells that need to be treated to the patient. After the blood is treated it is then returned to the patient. This procedure allows the patient to be treated with minimal side effects. "This treatment will potentially provide an additional means of controlling graft vs. host disease, a process that often impairs quality of life and functional capacity in patients who have undergone marrow transplantation," said Jane Liesveld, M.D., Director of Bone Marrow Transplant Unit.

62. BioSpace : CCIS : Immune Disorders infection (nonspecific); graft vs. host disease; Hepatitis-A; Hepatitis-B;Hepatitis-C; Hepatitis-E; Hepatitis-G; Hepatitis-H; Herpes Simplex http://www.biospace.com/ccis/list_rx.cfm?MetaRXID=13

63. BioSpace Glossary : Definitions graft vs. host disease. A reaction of donated bone marrow against a patient's owntissue. Also called GVHD. See Also. graft vs. host disease. Related News. http://www.biospace.com/gls_detail.cfm?t_id=1316

64. U-M CCC - Michigan Oncology Journal Summer 99 program. Jamie brings to Michigan a highly successful investigativeprogram on the pathophysiology of graft vs. host disease (GVHD). http://www.cancer.med.umich.edu/news/moj99su.htm

MOJ Archive Michigan Oncology Journal Summer 1999 Advancements in Clinical and Basic Science Research from the University of Michigan Comprehensive Cancer Center From the Editor The Separation of Graft-Versus Leukemia and Graft-Versus-Host Disease Through Cytokine "Shields" Low-Intensity Preparative Regimen and Allogeneic Peripheral Blood Stem Cell Transplantation Stem Cell Transplantation for Multiple Myeloma ... Of Interest Editor Laurence H. Baker, D.O. Deputy Director and Director for Clinical Research U-M Comprehensive Cancer Center Assistant Editor Maria McKinney White Director Marketing and Public Relations Michigan Oncology Journal University of Michigan Comprehensive Cancer Center From the Editor This issue of the Michigan Oncology Journal introduces Jamie Ferrara. Jamie joined our faculty last fall after an intensive (and I would add highly successful) search for the directorship of our Blood and Marrow Transplantation Program. Sam Silver, who had initially organized our transplant group, became the director of the Cancer Center's outreach program. Jamie brings to Michigan a highly successful investigative program on the pathophysiology of graft vs. host disease (GVHD). He is also a trained pediatrician, and that fact allowed us to combine the medical and pediatric transplant efforts into a single program under his direction.

65. Kennedy Krieger Institute Pediatric Rehabilitation Clinic brain injury, other acquired brain injuries (eg due to infections, strokes, etc),spinal cord injury, transverse myelitis and chronic graft vs. host disease. http://www.kennedykrieger.org/accessible/kki_cp.jsp?pid=1411

66. BMT (Transplants) Return to top. graft vs. host disease (GVHD) -. Comparison of chronic graft-versus-hostdisease after transplantation of peripheral blood stem cells vs. http://www.lymphomation.org/allobmt.htm

ask question or sign Guest Book About NHL Advocacy Art Clinical trials ... WebCasts Bone Marrow Transplants Main Allogeneic Autologous Cord Blood ... Treatment Overview Last update: H ere's we provide resources and information about transplants for the treatment of lymphoma. Main Menu Allogeneic Transplant Stem cells harvested from Donor Autologous Transplant Stem cells harvested from ... Patient Stories Please call the National Bone Marrow Donor program at 800 MARROW2 ( 800 627-7692 ) and become a registered donor. Background / When to Consider Transplants: Allogeneic vs Autologous Transplantation for Indolent Non Hodgkin's Lymphoma, Bruce Cheson, MD National Cancer Institute John G. Gribben, MD Harvard Medical School - PAL/Healthology Are transplants effective in treating lymphoma? Dr Vose - HealthTalk Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers - cis.nci.nih.gov

67. Unrelated Donor Transplantation - University Of Minnesota Cancer Center initial engraftment. Twentyone percent of those cases survive. Complicationsof BMT graft vs. host disease (GVHD). The major biological http://www.cancer.umn.edu/page/research/trsplant/bmt_urd.html

document.write(secondIm) Introduction Research areas: Immunotherapy Stem Cell Biology ... Contact the BMT Program Related links: Children's Cancer Research Fund Care Partners Research Programs Breast Cancer Cancer Progression and Metastasis Carcinogenesis and Chemoprevention Genetic Mechanisms of Cancer ... Transplant Biology and Therapy Unrelated donor transplantation Unrelated donor (URD) transplantation has increased rapidly over the last 10 years. More than 700 unrelated donor bone marrow transplants and over 100 unrelated donor cord blood transplants have been performed at the University of Minnesota. Important issues regarding such transplants include: Availability of donors Outcomes of unrelated donor BMT Complications: Engraftment Complications: Graft vs. Host Disease ... Quality of life following unrelated donor BMT Availability of donors The use of marrow from unrelated donors has expanded greatly since the first case reports of such procedures in the early 1980s. The development of this therapy has been made possible by the successful establishment and expansion of the National Marrow Donor Program (NMDP) The NMDP now has more than 6 million potential donors registered, and through international agreements can facilitate access to more than 7 million potential donors worldwide.

68. Graft Versus Host Disease GVHD Clinical Significance of Skin Biopsies in the Diagnosis and Management of graftvs-HostDisease in Early Postallogeneic Bone Marrow Transplantation Youwen Zhou http://www.edae.gr/graft.html

HELLENIC ASSOCIATION DERMATOLOGY - VENEREOLOGY GRAFT VERSUS HOST DISEASE (GVHD) Acute Graft Versus Host Disease Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect Advances in Small Bowel and Multivisceral Transplantation Jacques Pirenne, MD, PhD. XVIII International Congress of the Transplantation Society Approaches to Treating Graft-Versus-Host Disease Approaches to Treating Graft-Versus-Host Disease. Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation Public Health Service National Institutes of Health bone marrow transplants Bullous Esophagitis and GVHD diagnosishealth. BULLOUS ESOPHAGITIS DUE TO CHRONIC GVHD Causes, incidence, and risk factors graft-versus-host reaction Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. Grundmann-Kollmann M, Behrens S, Gruss C, Gottlober P, Peter RU, Kerscher M. Department of Dermatology, University of Ulm, Germany. J Am Acad Dermatol 2000 Jan; 42(1 Pt 1): 134-6. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy Grundmann-Kollmann M, Behrens S, Gruss C: J Am Acad Dermatol 2000 Jan; 42(1 Pt 1): 134-6[Medline].

69. Genetic Variability May Predict Severity Of Side Effects From Methotrexate, A Co 220 bonemarrow transplant patients who received methotrexate, an antifolate drugused as standard therapy for preventing graft-vs-host disease, a common http://www.fhcrc.org/news/science/2001/06/25/MTHFR.html

HOME News and Events News Special Events News Releases ... Media Relations Information CONTACT: Kristen Woodward FOR IMMEDIATE RELEASE June 25, 2001 Genetic Variability May Predict Severity of Side Effects From Methotrexate, A Common Chemotherapy Drug DNA screening tool may be useful in tailoring treatments for cancer and other diseases SEATTLE – Nearly half of all Americans carry a genetic mutation that to some degree interferes with their ability to metabolize folate, a B vitamin found in fruits, grains, and dark green, leafy vegetables. Also available in supplement form as folic acid, this important nutrient perhaps is best known for its role in preventing birth defects in the brain and nervous system. People with sluggish folate metabolism in general are at no greater risk for disease than the rest of the population. However, when exposed to a poor diet or certain drugs, these people can suffer significant clinical consequences, particularly if they are among the approximately 10 percent of Americans born with the most limited ability to process this nutrient. Cornelia Ulrich, Ph.D., and colleagues from the Fred Hutchinson Cancer Research Center will report these findings in the July 1 issue of

70. Quest - Fall 2000 Hutchinson Center researchers have discovered a new treatment that may reduce orprevent graftvs.-host disease, a major complication following bone-marrow http://www.fhcrc.org/pubs/quest/fall00/research.html

HOME Visitor Center Publications Quest - Fall 2000 ... A Legacy of Life Research Notes Partners in Progress Hutchinson Heroes Events Roundup Gallery ... Quest Archive Hutch to serve as global hub for HIV vaccine and prevention: Two new international networks build on years of Hutch research on AIDS Capping years of leader- ship in a multitude of HIV research projects, the Hutchinson Center will take center stage in two landmark, international HIV-vaccine and HIV-prevention projects. Both funded by the National Institutes of Health, the HIV Vaccine Trials Network and the HIV Prevention Trials Network will dramatically expand international research on HIV, the cause of AIDS. The HIV Vaccine Trials Network will provide a comprehensive, clinically based, worldwide network to develop and test preventive vaccines for the virus that has caused a global epidemic affecting an estimated 40 million people. “This represents the development of a new global international clinical trials network to speed the development of an HIV vaccine,” says Dr. Larry Corey, head of the Hutch’s infectious diseases program and professor at the University of Washington. Corey will direct the network’s core operations center, which will be located at the Hutch.

71. Cryobanks International : FAQ graftvs-host disease Condition in which a donor's T cells attack the recipient'scells. Human leukocyte antigen (HLA) What is graft vs. host disease (GVHD)? http://www.cryo-intl.com/faq.html

Antibodies Substances formed by the body in response to the presence of antigen/allergen. Chemotherapy The treatment of cancer by chemicals and/or drugs. Cryopreservation Engraftment When stem cells colonize in the marrow space of the host and begin to divide and replicate. Graft-vs-host disease Condition in which a donor's T cells attack the recipient's cells. Human leukocyte antigen (HLA) Antigens expressed on the surface of leukocytes and most body cells which are determinants of graft rejection and are used for typing tissues of donor and recipient. Radiation therapy Cancer treatment using x-rays or other types of irradiation. Stem Cells Cord Blood Storage and Donation How Long Has Science Known About Human Cord Blood? France, 1988 - A team of doctors, including Dr. Eliane Gluckman , a member of the Cryobanks International S.A.M.B.A. performed the first human cord blood transplant into a child with Fanconi Anemia successfully. In 1991, a transplant was successfully performed on a child with chronic myelogenous leukemia. These initial accomplishments opened doors to use cord blood for situations where traditional bone marrow was routinely utilized. Since then, over 2,000 cord blood transplants have been performed. Cord blood has been used to treat malignancies such as Leukemias, Lymphomas (Hodgkin's Disease), Neuroblastoma, (Brain Tumor) and non-malignancies such as Sickle Cell Anemia, XLP Disease, SCIDS (Bubble-Boy Disease), Wiskott-Aldrich Syndrome, Beta-Thalessemia, Hunter's Syndrome, Fanconi Anemia, and Aplastic Anemia.

72. NIH News Release-Regression Of Advanced Kidney Cancer Seen With Allogeneic Stem The drug cyclosporine was administered to prevent rejection of the donor cellsand graft vs. host disease, a potentially lifethreatening complication that http://www.nhlbi.nih.gov/new/press/sep13-00.htm

NATIONAL INSTITUTES OF HEALTH National Cancer Institute National Heart, Lung, and Blood Institute EMBARGOED FOR RELEASE Wednesday, September 13, 2000 5:00 p.m. EDT Contact: NHLBI Communications Office NCI Press Office Regression of Advanced Kidney Cancer Seen With Allogeneic Stem Cell Transplantation Researchers at the National Institutes of Health (NIH) report that advanced kidney cancer, a disease notoriously resistant to therapy and usually fatal, can be completely or partially reversed in some patients with the use of blood stem cell transplants from a healthy sibling donor. Using this investigational approach, substantial and occasionally complete regression of widespread tumors was observed in the majority of 19 patients with treatment-resistant metastatic renal cell carcinoma who were treated at the National Heart, Lung, and Blood Institute (NHLBI) Stem Cell Transplant unit. This Phase I/II study appears in the Sept. 14, 2000, issue of the New England Journal of Medicine Principal investigator and lead author of the paper, Richard Childs, M.D., of NHLBI's Hematology Branch said, "Considering that there are no current treatments that benefit patients who have not responded to conventional therapy, we are very encouraged by the early high response rate in our first group of patients treated, with a few patients remaining completely free of cancer more than two years from the initiation of therapy." According to Childs, the overall response rate of greater than 50 percent in patients with treatment-resistant disease is remarkable, considering that current first-line therapy is effective in less than 20 percent of cases. Three patients (16 percent) had total regression of all metastases and seven (38 percent) showed partial regression of disease.

73. The Hebrew University Of Jerusalem School Of Pharmacy F., Goldenhersh, MA, Segal, V. and Nagler, A. . Nedocromil sodium amelioratesskin manifestations in a murine model of chronic graftvs.-host disease. http://eia.md.huji.ac.il:1050/Lec_Details.asp?Lecturer_ID=98

74. Viacord | Questions And Answers Back To Top. What is graft vs. host disease (GVHD)? GVHD is a conditionthat sometimes occurs following bone marrow transplants. http://www.viacord.com/QA/QA.asp?section=7&s=CordBlood

75. CRYOLIFE transplants? What is graft vs. host disease (GVHD)? How can cord bloodbe used? BACK TO TOP. What is graft vs. host disease (GVHD)? GVHD http://www.cryolife.com.hk/english/faq.htm

The Nature of Cord Blood What is cord blood? What are stem cells? What are the advantages of using cord blood? Cord Blood Transplantations How long have scientists known about human umbilical cord blood transplants? What is Graft vs. Host Disease (GVHD)? How can cord blood be used? Cord Blood Banking How is cord blood collected and stored? Is it painful or does it interfere in any way with the birthing process? Can stem cells be collected later in my baby's lifetime? How long can the cells be stored? ... What is the future of cord blood? Control of the Cord Blood Who control the use of the stored cord blood stem cells? Who can use cord blood? What is cord blood? Cord blood, or umbilical cord blood, is blood that comes from the umbilical cord connecting a newborn with its mother. When a baby is born, cord blood is usually discarded following delivery. However, cord blood carries vital power to save lives as this blood is rich in stem cells. People affected by certain cancers, blood disorders and immune system disorders may benefit from medical treatments involving stored cord blood stem cells. BACK TO TOP What are stem cells?

76. EMedicine - Graft Versus Host Disease : Article By Melanie K Kuechle, MD cytokine production and acute graftversus-host disease after allogeneic planus-likehistopathologic characteristics in the cutaneous graft-vs-host reaction. http://www.emedicine.com/derm/topic478.htm

document.write(''); (advertisement) Home Specialties CME PDA ... Patient Education Articles Images CME Patient Education Advanced Search Link to this site Back to: eMedicine Specialties Dermatology Allergy And Immunology Graft Versus Host Disease Last Updated: March 19, 2003 Rate this Article Email to a Colleague Synonyms and related keywords: GVHD, allogenic hematopoietic cell transplantation, HCT, autologus hematopoietic cell transplantation, solid organ transplants, blood transfusions, maternal-fetal transfusions AUTHOR INFORMATION Section 1 of 11 Author Information Introduction Clinical Differentials ... Bibliography Author: Melanie K Kuechle, MD , Assistant Professor, Department of Medicine, Division of Dermatology, Department of Internal Medicine, Division of Dermatology, University of Washington School of Medicine Melanie K Kuechle, MD, is a member of the following medical societies: Alpha Omega Alpha American Academy of Dermatology Society for Investigative Dermatology , and Washington State Medical Association Editor(s): Evan Farmer, MD

77. Methodist Healthcare System physician with the Texas Transplant Institute, shows promising results in treatingtransplant patients’ steroidresistant graft vs. host disease (GVHD) with http://media.sahealth.com/viewpressrelease.asp?MediaID=479

78. Clinical Tissue Transplantation For example, failure of liver transplants is more often due to vascular complicationsand blood seepage than from rejection. graft vs. host disease. http://imcip.gsm.com/integrated/immu/im/immuno/ch13/grafhost.htm

Clinical Tissue Transplantation Organ and tissue transplantation has advanced from an experimental procedure used only in life-threatening, emergency procedures to the treatment of choice for a wide range of clinical conditions. It includes transplants for life-enhancement as well as the traditional lifesaving. The table at the right lists the most commonly transplanted tissues (except blood). The various tissues present the surgeon with different challenges. For example, failure of liver transplants is more often due to vascular complications and blood seepage than from rejection. Graft vs. host disease Most bone marrow transplants are done on patients who are immune deficient, either naturally (eg, a genetic defect) or artificially (eg, cytotoxic drug and radiation treatment of cancer). This means the patient does not have a functioning immune system to reject the transplant. However, the transplant does contain immunologically competent cells to reject the recipient! This situation is called graft vs. host disease (GvH) and is probably the greatest problem in the use of bone marrow transplants, affecting 50-70% of marrow recipients. Stimulated Th1 cells produce cytokines that generate inflammatory reactions in the skin, liver, and GI tract. It can lead to liver failure and GI hemorrhage. Promising efforts are being made to "purge" the donor bone marrow of T cells, so they are not available to attack the host. However, some evidence shows that a low level GvH may be beneficial in some situations. In artificially immunosuppressed individuals, a few donor lymphocytes may overwhelm any remaining host T cells and prevent graft rejection.

79. NMDP - News Releases Dr. Lee will be investigating The Morbidity and Mortality of Chronic graft vs.host disease. Dr. Lee's goal is to develop standardized criteria for judging http://www.marrow.org/NEWS/RELEASES/bos_trans011599.html

Home Current News Releases > Story Massachusetts And Minnesota Doctors Receive First Grants to Study Complications After Marrow Transplants The Marrow Foundation, National Marrow Donor Program MINNEAPOLIS 03/27/98 - Amy Strelzer Manasevit's wish to improve the lives of patients who receive bone marrow transplants comes true today when The Marrow Foundation and the National Marrow Donor Program® (NMDP) announce the first two Amy Strelzer Manasevit Scholars. Dr. Stephanie Lee of the Dana-Farber Cancer Institute in Boston, and Dr. Paul Orchard of the University of Minnesota in Minneapolis were selected, through a competitive process, to receive the two-year research grants. The doctors will receive their awards at a special presentation held as part of the Annual Meeting and Scientific Assembly of the American Society for Blood and Marrow Transplantation (ASBMT) in Miami Beach, Fla. Working in collaboration with The Marrow Foundation and the NMDP, Amy's family created the "Amy Strelzer Manasevit Scholars Program for the Study of Post-Transplant Complications" to carry out her wishes after she died of complications following an unrelated marrow transplant. Dr. Stephen Forman, head of the marrow transplant program at City of Hope National Medical Center in Duarte, Calif. chaired the new program's prestigious awards committee. Forman says, "This first-of-its-kind research initiative will fund six Scholars who will be engaged in basic research leading to clinical solutions for post-transplant complications to improve long term survival rates and the quality of life for transplant recipients."

80. THE MERCK MANUAL, Sec. 12, Ch. 149, Transplantation Intensive preparative regimens, effective graftvs.-host disease (GVHD) prophylaxis,treatment with cyclosporine-based regimens, and improvements in supportive http://www.merck.com/pubs/mmanual/section12/chapter149/149h.htm

This Publication Is Searchable The Merck Manual of Diagnosis and Therapy Section 12. Immunology; Allergic Disorders Chapter 149. Transplantation Topics [General] Immunobiology Of Rejection Kidney Transplantation Liver Transplantation ... Transplantation Of Other Organs And Tissues Bone Marrow Transplantation Over the past two decades, allogeneic bone marrow transplantation (BMT) has evolved from an experimental procedure reserved for patients with refractory leukemia into a rapidly expanding area of clinical investigation that offers potential cure for patients with aplastic anemia, acute and chronic leukemia, breast cancer, and selected types of lymphoma. The objective of BMT is to provide a healthy stem cell population that will differentiate into blood cells to replace deficient or pathologic cells of the host. Intensive preparative regimens, effective graft-vs.-host disease (GVHD) prophylaxis, treatment with cyclosporine-based regimens, and improvements in supportive care (eg, antibiotics, herpesvirus and cytomegalovirus prophylaxis) have brought significant improvements in long-term disease-free survival in patients undergoing BMT. Cytokine treatment after BMT (eg, with colony-stimulating factor) is being tested to see if engraftment can be improved or accelerated. Indications: Patients with acute myeloid or lymphoblastic leukemia may benefit from BMT. Patients with acute myeloid leukemia transplanted in first remission can now expect an approximately 50 to 60% likelihood of long-term disease-free survival. Similar probabilities are also achievable after transplantation of adults with acute lymphoblastic leukemia in first remissions. Probability of relapse correlates with remission status at the time of the transplant, ranging from 20% in first remission to 60% with more advanced disease. Long-term survival for patients with chronic myelocytic leukemia who receive BMT in the phase of remission is 60 to 70%.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 4     61-80 of 92    Back | 1  | 2  | 3  | 4  | 5  | Next 20